Way, way back in 2015 – seems like a lifetime ago, doesn’t it – the team at CIRM sat down and planned out our Big 6 goals for the next five years. The end result was a Strategic Plan that was bold, ambitious, and set us on course to do great things or kill ourselves trying. Well, looking back, we can take some pride in saying we did a really fine job, hitting almost every goal and exceeding them in some cases. So, as we plan our next five-year Strategic Plan, we thought it worthwhile to look back at where we started and what we achieved. Goal #3 was Partner.
In the musical “Fiddler on the Roof,” two of the daughters sing about their hopes of finding a husband, through the services of a matchmaker:
Matchmaker, Matchmaker,
Make me a match,
Find me a find,
Catch me a catch
While CIRM isn’t in the business of finding husbands for young ladies, we have set ourselves up as matchmakers of a very different kind. Over the past five years or more, we have actively sought deep-pocketed partners for some of the researchers we fund. You could say we are changing the last line in that verse to “Catch me some cash.” And we do.
Our goal is to help these researchers access the funding they’ll need to move their work into clinical trials and through the Food and Drug Administration (FDA) approval process, so they are available to people who need them. To do that, we created what we call our Industry Alliance Program (IAP).
The goal of the IAP is simple: to be proactive in creating partnerships between industry and our grantees, helping to develop direct opportunities for industry to partner with CIRM to accelerate the most promising stem cell, gene, and regenerative medicine therapy programs toward commercialization.
It takes a lot of money to move a promising idea out of the lab and into the arms, or other body parts, of patients; one recent estimate put that at around $1 billion. CIRM can help fund projects to get them off the ground and into clinical trials, but as you move to larger trials, they become much more expensive. The IAP brings in well-heeled investors to help cover those expenses.
Back in 2015, when we were developing our Strategic Plan, we made these partnerships one of our Big 6 goals. And, as with everything we did in that plan, we set an ambitious target of “partnering 50% of unpartnered clinical projects with commercial partners.”
So, how did we go about reaching that goal? Our Business Development Team (Drs Shyam Patel and Sohel Talib) worked with large companies to help identify their strategic focus and then provided them with non-confidential information about projects we fund that might interest them. If they saw something they felt had promise, we introduced them to the researchers behind that project. In essence, we played matchmaker.
But it wasn’t just about making introductions. We stayed involved as the two groups got to know each other, offering both scientific and legal advice to help them overcome any reservations or obstacles they might encounter.
So how did we do? Pretty good, I would have to say. By the end of 2020, we had partnered on 63% of unpartnered clinical projects, 72 events in total, generating almost $13 billion in additional investment in these projects. That money can help move these projects through the approvals process and ultimately, we hope, into the clinic.
But we’re not done. Not by a long shot. Now that we have achieved that goal, we have our eyes set on even bigger things. We are now working on creating a new Strategic Plan that considers bringing industry in to partner with projects at earlier stages, or creating public-private partnerships to ensure there is enough manufacturing capacity for all the new therapies in the pipeline.
We have a lot of work to do. But thanks to the passage of Proposition 14, we now have the time and money we need to do that work. We’ve got a lot more matchmaking to do.
